Miltuximab® for Therapeutic & Imaging Applications

Our patented antibodies target Glypican-1 (GPC-1), a protein overexpressed in prostate, pancreatic, bladder, esophageal and other solid tumors.
We are examining multiple mechanisms of action including:

  • Radio immunotherapy
  • Bispecific antibodies
  • Immune cell engagement and activation

We have now completed a first in-human trial using Miltuximab®, our anti-GPC-1 monoclonal antibody (ANZCTR registry).

The trial dosed 12 patients and no drug-related adverse events were observed.

Achievements

N

2016

Commenced First-in-Human trial of Miltuximab®

N

2017

The second stage of pioneering MILGa clinical trial of Miltuximab®

N

2018

Completion of accrual for clinical study of Miltuximab® in prostate, bladder and pancreatic cancers

2015 Eureka Prize

Excellence in Interdisciplinary Scientific Research

Major Australian prize for innovation awarded to our CEO, Brad Walsh, and university collaborators.

Find Out More Information

  • About our groundbreaking first-in-human trial of our novel cancer target >More
  • About how your company and Glytherix could partner to deliver better cancer therapeutics >More 

5 + 10 =

Address
Suite 2, Ground Floor, 
75 Talavera Road, 
Macquarie Park, NSW 2113, 
Australia

Phone
International +612 9850 4000
In Australia 02 9850 4000
Compare your time zone with Sydney here

Email
info@glytherix.com

Finding Us
We are based in Sydney, adjacent to one of Australia’s leading universities, Macquarie University, and the Macquarie University Hospital, one of our key collaborators.

Headquarters of Glytherix

Privacy Policy